Merck & CompanyvsNasus Pharma

MRK and NSRX stock compared: price, dividend, valuation and results, from SEC filings.

MRK

Merck & Company, Inc.

$143.37

Value $354B

-0.75%
MRK's page

Merck & Company (MRK) has a market value of $354B and Nasus Pharma (NSRX) $24M. Over the last year, with dividends, MRK moved +58.8% and NSRX -64.8%. Dividend yield: MRK 2.37%, NSRX none.

At a glance

The main figures of both. A bar only shows which number is larger, not which is better.

  • Market value

    MRK$354B

    NSRX$24M

    MRK is 15,064 times NSRX

  • Revenue, 12 months

    MRK$67.4B

    NSRX$1.2B

    MRK is 55 times NSRX

  • Net income, 12 months

    MRK$2.5B

    NSRX-$5.9M

  • Operating margin

    MRK–

    NSRX-0.4%

  • ROIC

    MRK3.9%

    NSRX-140.0%

    143.9 points apart

  • P/E

    MRK144.5

    NSRX–

  • Dividend yield

    MRK2.4%

    NSRX0.0%

    2.4 points apart

A fainter bar means a negative number. The 5-year return includes dividends.

The price over time

Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.

MRK+58.8%

NSRX-64.8%

50100150DecFebAprJunAugOct
Returns by period
PeriodMRKWith dividendsNSRXWith dividends
1 year since November 14, 2025+58.8%Price +54.3%-64.8%Price -64.8%

Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.

Every figure

As on each company's page. A description, not a recommendation: no one figure says which is better.

MRKMerck & CompanyNSRXNasus Pharma

Valuation

MRKNSRX
Valuation
Price$143.37$2.61
Market value$354B$24M
Enterprise value (EV)$399B$22M
P/E144.5–
P/E, 5-year median14.8–
P/B7.98.5
EV/EBIT83.7–
Free cash flow yield4.2%–

Results and growth

MRKNSRX
Results and growth
Revenue, 12 months$67.4B$1.2B
Net income, 12 months$2.5B-$5.9M
Free cash flow, 12 months$14.7B-$4.9M
Earnings per share, 12 months$0.98-$0.72
Revenue growth, year on year1.3%–
Revenue growth a year, past+9.4%over 5 years–
EPS growth a year, past+21.2%over 5 years–

Margins and returns on capital

MRKNSRX
Margins and returns on capital
Gross margin71.8%–
Operating margin–-0.4%
Net margin3.6%-0.5%
ROIC3.9%-140.0%
ROE5.2%–

Balance sheet

MRKNSRX
Balance sheet
Cash$9.7B$1.2M
Total debt$53.8B$118.0K
Net debt / EBITDA5.7–
Interest cover2.4×–

Dividends and buybacks

MRKNSRX
Dividends and buybacks
Dividend yield2.4%–
Dividend per share, 12 months$3.40–
Dividend growth a year, past+5.8%over 5 years–
Buyback yield1.4%–
Shareholder yield3.8%–

Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.

Questions: MRK or NSRX

Didn't find what you were looking for?

Ask us
Which is bigger, Merck & Company or Nasus Pharma?

By market value, Merck & Company ($354B) is about 15,064.4 times Nasus Pharma ($24M), at today's prices.

How did MRK and NSRX stock do over the last 1 years?

Since November 14, 2025, MRK's price moved +54.3% and NSRX's -64.8%. With dividends: MRK +58.8% (+58.8% a year), NSRX -64.8% (-64.8% a year). Past returns do not predict future ones.

Which pays the higher dividend, MRK or NSRX?

The dividend yield at today's price is 2.37% for Merck & Company and none for Nasus Pharma. Over the last twelve months they paid $3.40 and – per share.

Which has the higher profit margins, Merck & Company or Nasus Pharma?

Over the last twelve months, the net margin was 3.6% for Merck & Company and -0.5% for Nasus Pharma, and the operating margin – and -0.4%. Revenue was $67.4B and $1.2B.

Which is the better investment, Merck & Company or Nasus Pharma?

The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.

Other comparisons

With each of the two, and with the largest in its sector.

Related pages

The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.

Descriptive data from SEC filings and market prices.